DarioHealth (NASDAQ: DRIO), a leader in the global digital health market, is reporting on new research presented last week at the Diabetes Technology Society 2023 Meeting. According to the announcement, the new study demonstrates the value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and prediabetes; the results emphasize the value of a whole-health approach managing chronic conditions as well as supporting those using GLP-1s, or anti-obesity medication. Specifically, the study evaluated the blood glucose and walking data of 989 Dario users in an effort to explore and understand the impact of integrating clinical and behavioral data in a single digital app-based experience. The results showed significantly reduced blood glucose levels in the first four months that participants used Dario as well as increased step levels in the same timeframe; those results were maintained for 12 months. The research was conducted in partnership with the Integrative Pain Laboratory at the School of Public Health at the University of Haifa. “Improving health behaviors is the key to improving outcomes, and Dario is intensely focused on the intersection of those behaviors with clinical intelligence gained from more than a decade of consumer engagement,” said Dario chief medical officer Omar Manejwala, MD, in the press release. “We are excited to see this new study shed light on the impact a singular focus on whole health can have for our members and our partners.”

To view the full press release, visit https://ibn.fm/RltGa

About DarioHealth Corp.

DarioHealth Corp. is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multichronic condition digital therapeutics platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. The company’s user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results, and making the right thing to do the easy thing to do. Dario provides its highly user-rated solutions globally to health plans and other payors, self-insured employers and providers of care as well as directly to consumers. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN